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Abstract 
Down syndrome, or trisomy 21, is the most common autosomal aneuploidy resulting in 
a number of phenotypes such as mental retardation, craniofacial bone differences, early onset 
of Alzheimer's disease, congenital heart failure, and notably an Increased incidence of leukemia 
and a reduced Incidence of solid tumors. This study Investigated a hypothesized tumor 
suppressor gene responsible for the phenomenon of a decreased risk of solid tumors In 
Individuals with Down syndrome. Genetically engineered mice that were either trisomic or 
monosomic for the 33 genes of the Down syndrome critical region or heterozygous for carbonyl 
reductase 1 were bred to mice susceptible to developing mammary tumors. The hypothesized 
numerically altered tumor suppressor genes on mouse chromosome 16, conserved with human 
chromosome 21, were expected to affect tumor growth and metastasis In the resultant mice 
when compared to their unaltered, wild type littermates. The mice were genotyped and 
assessed for tumor latency, multiplicity, and total tumor burden. Lungs were obtained for lung 
metastasis counts and analysis. Due to the relatively low sample sizes and qualitative data 
analysis, no definitive conclusions can be made; however, lack of trends Indicative of a tumor 
suppressor gene affecting the experimental mice suggest this breast cancer model is unaffected 
by theorized suppressors. Excluding the potential tumor suppressor genes In these models 
narrows the scope ofthe search for such a tumor suppressor. Efforts could be shifted toward 
other Down syndrome mode.ls In hopes of identifying a tumor suppressor gene that enables all 
people, not just those with Down syndrome, to be protected from the development and 
invasive progression of cancer through the upregulatlon ofthat specific gene. 
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Introduction 
Down syndrome (OS) is a genetic condition In which there Is a change in the normal 
number of chromosomes, otherwise known as an autosomal aneuploidy (Reeves et al., 2001). 
Caused by a triplication of a portion or all of chromosome 21 as a result of a nondisjunction 
event in meiosis, Down syndrome results in many different phenotypes. Mental retardation Is 
at the forefront of such phenotypes and is characterized by reduced size and shape ofthe brain 
and cognitive Impairment (Reeves et al., 2001). 
It was not until1959 that Down syndrome was identified as the result of trisomy 21. 
Not until chromosomes could be analyzed in more detail due to the enhancement of 
technologies did researchers identify individuals who were trisomic for just part of 
chromosome 21 (Olson et al., 2004). Due to the differences In the regions of chromosome 21 
that are triplicated In some individuals with Down syndrome, questions as to which genes on 
the chromosome are responsible for conferring the Down syndrome phenotypes were raised. 
The chromosomes of several individuals with Down syndrome were cross-referenced to their 
phenotypes, and a small region of overlap of approximately 5.4 Mb within chromosome 21 was 
identified to be shared by the individuals with the common phenotypes (Delabar et al., 1992; 
Olson et al., 2004). This region was termed the Down syndrome critical region, or DSCR, and 
spearheaded a new theory as to the critical nature of 33 dosage sensitive genes to the 
expression of Down syndrome characteristics (Delabar et al., 1992). The OS phenotypes 
attributed to the dosage of the DSCR included craniofacial abnormalities, mental retardation, 
muscle hypotonia, short stature, joint hyperlaxity, and a number of other deformities (Aldridge 
et al., 2007; Olson et al., 2004). However, Olson et al. (2004) refuted the claim that the 
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craniofacial, memory, and learning phenotypes shared by the individuals compared were 
attributed to dosage of the 33 genes of the DSCR when engineering mice that were solely 
trisomic for the DSCR and not observing the phenotypes in resultant mice. 
Individuals with OS have a relatively shorter lifespan than the general population; 
however, recent medical advancements and knowledge have aided In the treatments of this 
chromosomal disorder, therefore extending the life expectancy of this group (Sullivan et al., 
2007). The increased survival of Individuals with Down syndrome allows more time for the 
development of problems and diseases such as cancer, specifically solid tumors. This allows for 
a comparison of solid tumor Incidence In older individuals with Down syndrome to the older 
general population (Zorick et al., 2001). 
Cancer is a major cause of death in the United States, second only to heart disease. It Is 
expected that there will be 1.5 million new cancer cases diagnosed this year; over 500,000 of 
those cases will result in death (American Cancer Society, 2009). Cancer is characterized by 
abnormal cell growth and proliferation synonymous with the term neoplasm, or new growth of 
tissue (American Cancer Society, 2009). Tumors, -or neoplasms, can either be classified as 
benign, meaning noninvasive, or malignant (American cancer Society, 2009). Malignant 
neoplasms are able to invade surrounding tissues and colonize different organs by 
metastasizing, or spreading through the circulatory system, to another site in the body 
(Pedraza- Farina, 2006). 
cancers originate from a single cell that has undergone a mutation caused by intrinsic 
or extrinsic factors, such as.carcinogens, that trigger genetic abnormalities in DNA (Alberts et 
al., 2008; Le Voyer et al., 2001). Compounded by further cancerous mutations In progeny, 
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cancer cells evolve, multiply, and spread due to a lack of response to cell signaling pathways 
that enable normal cells to respond to environmental signals and processes that keep cell 
proliferation under control, such as cell check-point regulation and apoptosis (Pedraza- Farina, 
2006). Contributing to tumor survival and evolution are the stromal cells which make up a 
tumor's microenvironment and provide vasculature to the tumor t~rough the process of 
angiogenesis, or formation of new blood vessels (Alberts et al., 2008; Laffin et al., 2008; Llfsted 
et al., 1998). The newly formed network of supply vessels enables tumor cells to invade the 
basal epithelial basement membrane, Initiating the metastatic stage and granting access to the 
circulatory and lymphatic systems (Lifsted et al., 1998). Cancer development requires many 
steps governed by multiple factors; genetic background and environment can accelerate the 
onset of most cancers and are studied in conjunction with the cellular mechanisms resulting In 
cancer to further elucidate its prevalence (Alberts et al., 2008). 
Multiple population studies have been conducted regarding the Incidence of different 
cancers in Individuals with Down syndrome. Down syndrome was found to be the second most 
common contributor to cancer In children 15 years of age or younger (Satg~ et al., 1998). 
Leukemia, a hematopoietic neoplasm that Is characterized by cancerous blood cells, manifests 
frequently In the first four years of life in individuals with Down syndrome (Haste et al., 2000). 
In two studies on different cohorts of Down syndrome Individuals, cancer was the fifth and sixth 
most frequent cause of death In the respective populations as a result of the increased 
incidence of leukemia (Satge et al., 1998). 
A study conducted In Denmark by Hasle and his colleagues was comprised of 2814 
individuals with Down syndrome (2000). Standard Incidence ratios (SIRs) and 95% confidence 
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intervals were calculated to determine the significance of the results of the study. The SIRs 
compare the observed number of cancer cases in Individuals with OS divided by the expected 
number in the general population In order to evaluate If a deviation has occurred from the 
expected incidence. The 95% confidence Intervals reflect the range In which the data will lay 
95% of the time. Intervals excluding the value of one are considered significant. The expected 
case numbers were determined by calculating age and sex-specific person-years for individuals 
with OS and then multiplying by the incidence rates of the corresponding population group, 
ensuring the groups were age- and sex-matched (Hasle et al., 2000; Patja et al., 2006}. Thirty-six 
leukemia cases were observed, significantly higher than the 2.04 cases expected [SIR 17.6 (95% 
Cl 12.4-24.40] (Hasle et al., 2000). 
A similar study conducted In Australia also found an increased Incidence of leukemia 
cases In children In the Down syndrome population of 1298 individuals who were registered 
with the Disability Services Commission (DSC) of Western Australia and the State Cancer 
Registry (WACR) (Sullivan et al., 2007). Using the same methods (SIRs and 95% Cis) to compare 
the number of observed cases of leukemia, it was determined that 12 cases of leukemia were 
observed when only 0.19 were expected [SIR 61.61 (95% Cl31.84-107.62)]. However, the 
expected number of cases was determined and age-standardized by using age-group specific 
rates that were provided by the WACR (Sullivan et al., 2007). Additionally, a study that took 
place in Finland, conducted by Patja and colleagues, found results similar to those of Sullivan et 
al.(2007} and Hasle et al. (2000). The cohort consisted of 3,581 subjects with Down syndrome 
as determined by the National Registry of Finnish persons with intellectual disability (Patja et 
al., 2006). Ofthe 3,581 study subjects, 22 cases of leukemia were observed when only 2.1 cases 
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were expected [SIR 10.5 (95% Cl 6.6-15.8)) (Patja et al., 2006). Together, the studies conducted 
In Denmark (Hasle et al., 2000), Australia (Sullivan et al., 2007), and Finland (Patja et al., 2006) 
suggest that with an extra copy of chromosome 21, the Incidence of leukemia Is Increased in 
populations worldwide. 
Although Individuals with Down syndrome have an increased incidence of leukemia, 
studies also have shown a decreased Incidence of solid tumor formation. The study conducted 
In Denmark by Hasle and colleagues counted 24Jnstances of solid tumors (Haste et al., 2000). 
The instances of solid tumor formation were significantly lower than the 47.77 tumors expected 
[SIR 0.50 (95% Cl 0.32-D.75)], only half of the expected number of solid tumors (Haste et al., 
2000). Sullivan and colleagues' Australian study also exhibited a decreased incidence of solid 
tumors In the Down syndrome cohort of 1298 individuals (Sullivan et al., 2007). When 
comparing the number of cases of solid tumors In the population of DS Individuals to the 
expected cases, Sullivan and colleagues found that only 44% [SIR 0.44 (95% Cl 0.19-0.86)] of 
solid tumors expected were observed in the cohort (Sullivan et at., 2007). The study conducted 
by Patja and colleagues In Finland concluded with similar observations of solid tumor incidence. 
Of the 56 cases of solid tumors that were expected, only 32 cases were observed. Comparable 
to the conclusions made concerning the incidence of leukemia in the multiple studies, It can be 
concluded that Individuals with OS have a reduced Incidence of solid tumors compared to that 
of the general population. However, metastasis development and counts were not considered 
and measured In these studies (Haste et al., 2000; Patja et al., 2006; Sullivan et al., 2007). 
From these results, It has been suggested that a tumor suppressor gene is located on 
chromosome 21, thus affecting the formation of solid tumors in individuals with DS who 
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possibly have three copies of the tumor suppressor (Hasle et al., 2001). Tumor suppressor 
genes are specialized genes that work to regulate cellular activities, such as division and 
programmed cell death, or apoptosis (Alberts et al., 2008; Sherr, 2004). Initiated by DNA 
damage, tumor su'ppressor genes are activated by a series of enzymes that increase the 
transcription pattern of a protein responsible for arresting the cell cycle of the damaged cells, 
effectively halting replication (Alberts et al., 2008). Once division Is halted, the tumor 
suppressor can signal the Initiation of apoptosis by activating the transcription of proapoptotic 
proteins that are responsible for triggering the Intrinsic activation of caspases, proteases.that 
effectively eliminate the potentially dangerous cell (Alberts et al., 2008). Mutations in tumor 
suppressor genes are generally recessive, meaning both copies need to be deleted, Inactivated, 
or silenced for phenotypic expression, or tumor suppressor loss-of-function, to occur (Alberts et 
al., 2008; Chial, 2008). However, sporadic inactivation of these genes or Inheriting only one 
functional gene predisposes ~ne toward developing cancer following a single event or 
disruption In the other functional tumor suppressor gene in any cell in the body (Chial, 2008; 
Sherr, 2004). Altered cells without these genes that either encode for DNA repair enzymes, or 
transcription factors that increase enzyme synthesis through increasing their corresponding 
gene's transcription, may Induce a selective advantage on mutated cells that results In their 
unchecked growth and proliferation (Chial, 2008; Sherr, 2004). 
Researchers have proposed which genes on chromosome 21 could be potential tumor 
suppressor genes responsible for the reduced Incidence of solid tumors. Zorick and colleagues 
observed In Down syndrome Individuals increased levels of endostatln, a protein encoded by a 
gene on chromosome 21 that inhibits angiogenesis In certain solid tumors. Angiogenesis Is a 
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critical step In tumor growth and proliferation, and Its dampened effect caused by a protein 
encoded by a gene on chromosome 21 highlights the suppressive capabilities of the 
chromosome (Zorick et al., 2001). 
Sussan and colleagues used multiple mouse models In order to investigate the 
relationship between OS and cancer. When the Apcgene was mutated, Intestinal tumors 
developed. Heterozygous ApcMin mice were crossed to the different OS model mice and tumor 
numbers were assessed (Sussan et al., 2008). Mice trisomic for a portion of the orthologous 
mouse chromosome 16 exhibited a reduction In tumor number, while mice monosomic for the 
same portions exhibited an increase in tumor number. In addition, the action of the ETS2 gene, 
a gene on mouse chromosome 16 previously believed to have proto-oncogenic character, was 
observed Individually. Surprisingly, ETS2 appeared to have a protective effect against Increased 
tumor number when its copy number was increased, proposing another possible tumor 
~~repressor'' or suppressor within the OSCR (Sussan et al., 2008}. 
Another theory involves the 51M2 gene on chromosome 21 within the OSCR which 
works to decrease migration, proliferation, and invasion of cells, therefore showing an 
Involvement In the tumor formation process (Kwak et al., 2007; Laffin et al., 2008). Kwak and 
colleagues assessed mRNA levels of SIM2 and various lsoforms in normal breast tissue and 
breast tumor cells. SIM2 was detected at highest levels in the normal tissues and decreased In 
the breast cancer progression series and other .cancer lines {Kwak et al., 2007). 
Immunohistochemical analysis of normal and cancerous br~ast tissues confirmed that SIM2 was 
lost with the development of cancer, suggesting cancerous tissue gains the ability to grow, 
proliferate, and Invade with the loss of 51M2 (Kwak· et al., 2007). In cancer cells transduced with 
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a SIM2-contalng vector, cell growth, proliferation, and invasion were assessed in vitro and 
markedly reduced compared to cells transduced with control vectors (Kwak et al., 2007). 
Similarly, Laffin et al. investigated the malignant changes associated with the loss of 51M2 in 
mouse mammary glands (2008). 51m2-/- mouse mammary glands and 51M2-lacking cells 
exhibited Increased proliferation and invasion of the stroma, resulting in Increased 
tumorigenesis (Laffin et al., 2008). 
Conversely, DeYoung and colleagues found 51M2 genes highly expressed in tumor cells 
versus other normal tissues. The Increased 51M2 expression presumably led to more cancer, 
opposing the hypotheses of Kwak et al. (2007) and Laffin et al. (2008). DeYoung's 
characterization of 51M2 suggests that 51M2 is acting as an oncogene, furthering cancer 
development Indicated by Increased expression In tumor cells, rather than a tumor suppressor 
as suggested by other data (DeYoung et al., 2003). 
Ryeom and colleagues have observed the targeted deletion of the D5CR1 gene, found 
within the D5CR, In mice and observed that this biochemical pathway Inhibitor can act as either 
a tumor suppressor or oncogene, depending on a delicate equilibrium of DSCRl expression and 
calclneurin activity (Ryeom et al., 2008). These opposing discoveries highlight the elusiveness of 
the role of the genes on chromosome 21 and their dosage-dependent nature. 
The proximal edge of the DSCR Is defined as the carbonyl reductase gene {CBRl). CBRl 
encodes an NADPH-dependent oxidoreductase enzyme from the family of short chain 
dehydrogenases/reductases that are able to reduce carbonyls, both endogenous and 
xenobiotlc, Including those of prostaglandins, steroids, quinones, and anthracyclines (Forrest & 
Gonzalez, 2000; Hoffmann & Maser, 2007; Takenaka et al., 2005). While human CBRl was first 
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mapped to chromosome 21, In mice, a highly conserved Cbr1 gene with 82% homology was 
mapped to mouse chromosome 16 (Forrest & Gonzalez, 2000). Known for its ubiquity 
throughout bodily tissues, carbonyl reductase (CBRl) enzyme has numerous substrates and 
consequently several hypothesized functions in biochemical reactions In the body. One role not 
fully understood Is CBRl's intervention in mutagenesis and carcinogenesis (Ismail et al., 2000; 
Takenaka et al., 2005). Initially, a study conducted by Ismail et al. in 2000 related CBR1 to 
cancer progression, suggesting the enzyme, through an unknown mechanism, facilitated the 
metastatic process associated with malignancy. In vitro, cell lines from a mouse lung cancer line 
showed an Increased metastatic potential in conjunction with a low expression of mouse Cbr1. 
Upon transfecting sense Cbr1 mRNA into these metastatic cells through and subsequently 
injecting them into mice, metastasis was reduced. Conversely, high levels of Cbr1 were 
observed in cells with a decreased metastatic potential. Upon transfectlon of cells from this line 
with antisense Cbr1 mRNA and subsequent Injection into mice, metastasis was increased, thus 
implicating Cbr1 as a potential metastasis suppressor gene (Ismail et al., 2000). 
Further Investigation of CBR1 in various cancers was performed by Takenaka et al. 
(2005) and Umemoto (2001), observing poor survival in patients with low expression of CBR1in 
non-small-cell lung tumor tissue and epithelial ovarian tumor tissue, respectively. Both 
angiogenesis and tumor progression were Inversely associated with CBRl expression in non-
small-cell lung tissue; when CBR1 expression was high, a 68.3% survival rate over five years was 
observed compared to a 36.5% survival rate for patients with low expression levels (Taken aka 
et al., 2005). Comparably, Umemoto et al. (2001) found In patients with CBR1-posltlve epithelial 
ovarian cancer tissue a higher survival rate of 86.1% over a five year period, whereas those with 
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CBR1-negatlve cancerous tissue exhibited a lower survival trend of 62.7% (Umemoto et al., 
2001). This evidence seems to support CBR1's role as a potential tumor or metastasis 
suppressor, possibly due to its ability to reduce prostaglandin E2 (PGE2), a tumor growth Inducer 
that when oxidized can promote angiogenesis by enhancing vascular endothelial growth factor 
(VEGF) and Inhibit apoptosis leading to tumor and metastasis development (Scheiber et al., 
1992). Halting the development of an extensive supply network could possibly lead to the 
Inhibition of malignant tumor development and progression. Because CBRlls found 
ubiquitously throughout tissues In the body and Is Implicated in numerous biochemical 
pathways and processes, including carcinogenesis, angiogenesis, and metastasis, CBR1 may 
prove to have tumor suppressive capabilities in vivo (Forrest & Gonzalez 2000; Ismail et al., 
2000). 
In order to study the phenomenon of a reduced number of solid tumors and metastasis 
in conjunction with a triplication of the OSCR or alterations to Cbr1, mouse models have been 
used. Mice, being a model organism, have many genes that are homologous, or relatively 
comparable, to human genes. Consequently, those· genes can be manipulated in mice to help 
predict what would happen In humans with similar genetic alterations; therefore, if a 
suppression of tumors is observed In mice, those phenotypes may be applied to or mimicked in 
humans. Additionally, mice are small, easily maintained, and reproduce very quickly, making 
results available fairly quickly and ethically (Suckow et al., 2001). 
TslRhr mice are segmentally aneuploid with a triplication of the OSCR while Ms1Rhr 
mice have a deletion of the same OSCR region. At Johns Hopkins University, these mice were 
created using embryonic stem cells from 129s6/SVE mice. Using ere-mediated recombination 
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between loxP sites on the homologous pair of chromosomes, duplication and deletion of the 
DSCR on mouse chromosome 16 was accomplished (Olson et al., 2004). Gene targeting was 
similarly conducted to create the null Cbrl allele and consequently Cbr1+/- mice. Following 
construction and transfectlon of the vector without a Cbr1 allele Into stem cells, hygromycln 
resistant cells were selected and screened for via PCR and Southern blotting {Olson et al., 
2003}. Once these recombinants were created, Injected into blastocysts, and reintroduced Into 
pseudo-pregnant mothers, chimeric mice were born. The chimeras were then screened for the 
ability to transmit the altered chromosomes in their germ-line by breeding the DSCR chimeras 
to a 86 strain of mice and the Cbr1 null chimeras to a 129SVE strain of mice. Ms1Rhr, Ts1Rhr, 
and Cbrl +/- mice were born and found to be fertile, however, homozygous null Cbrl mice 
proved fetal lethal (Olson et al., 2003; Olson et al., 2004}. 
In order to study mammary tumors, a transgenic strain of mice genetically engineered 
to produce solid tumors in the mammary glands has been used. Guy and colleagues in 1992 
created a PyVT strain that includes the PyVT (polyomavlrus middle T antigen) oncogene and the 
MMTV (mouse mammary tumor virus) promoter region allowing for the production of solid 
tumors specifically in the mammary glands that have metastatic potential to the lungs (Guy et 
al., 1992). The PyVT model has been widely studied to analyze the underlying mechanisms of 
both oncogenesis and metastasis and the direct connection between models and humans 
(Maglione et al., 2001). This model is relatively easy to work with because the transgenic mice 
are able to develop tumors as early as four weeks of age, including the potential to develop 
lung metastases (Lin et al., 2003). Tumors are able to develop at multiple sites In the mammary 
glands, superficial to the body cavity (Guy et al., 1992). This PyVT model of cancer mirrors the 
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changes In tumors that take place In humans as they progress from noninvasive to Invasive to 
metastatic (Lin et at., 2003). 
The purpose of this study was to determine whether the incidence of solid tumors in the 
mammary glands of the mouse models would be affected by the triplication of the DSCR, 
deletion of the DSCR, or deletion of Cbr1 by breeding the segmentally aneuploid TslRhr and 
MslRhr mice and Cbr1 null mice to PyVT mice and observing the production of solid tumors and 
lung metastases. 
Methods 
Three mouse models were used to study the incidence of solid tumors in parallel studies 
addressing mammary tumor and metastasis development in mice. In the first study, in order to 
determine If there was a tumor suppressor in the DSCR, mice with one, two, or three copies of 
the DSCR were generated through breeding. TslRhr (Johns Hopkins), mice with three copies of 
the DSCR, were bred on a C57B16/J (B6) background. MslRhr (Johns Hopkins), mice with one 
copy of the DSCR, were bred on an Fl C57B16/J x C3He/J (B6C3) background. Each of their 
respective wild type B6 (The Jackson Laboratory) and B6C3 (The Jackson Laboratory) strains 
were used to maintain the TslRhr and MslRhr lines. Experimental mice were generated by 
crossing FVBPyVT (PyVT) mice to mice with chromosome 16 alterations. PyVT mice were 
crossed to wild type FVB (MMHCC) in order to maintain PyVT lines. 
TslRhr mice were bred to PyVT mice In order to assess tumor formation in the 
mammary glands when trisomic for the DSCR. The ratio of expected progeny was as follows: 
25% TslRhr PyVT, 25% TslRhr, 25% PyVT, and 25% wild type. MslRhr mice were bred to PyVT 
mice in order to assess tumor formation In the mammary glands when monosomic for the 
14 
Ten ley Rawlings 
DSCR. The ratio of expected progeny was as follows: 25% MslRhr PyVT, 25% MslRhr, 25% 
PyVT, and 25% wild type. 
The second study included mice engineered to be heterozygous knockout for the Cbrl 
gene, another hypothesized tumor suppressor gene at the proximal edge of the DSCR. 
B6Cbr1+/- (Johns Hopkins) were bred and maintained on a C57B16/J background and 
129Cbr1+/- (Johns Hopkins) were bred and maintained on a 129SVE background. In order to 
assess tumor formation In the mammary glands when either heterozygous(+/·) or homozygous 
(+/+)for the Cbrl gene, experimental mice were generated by crossing B6Cbr1+/- and 
129Cbr1+/· mice to PyVT mice. The ratio of expected progeny was as follows: 25% Cbrl+/-PyVT, 
25% Cbr1+/-, 25% Cbrl+/+PyVT, and 25% Cbr1+/+ (wild type). 
Matings were expected to follow Mendelian genetics. Progeny were genotyped for the 
PyVT oncogene to ensure that tumors would form. All mice that did not contain the oncogene 
were euthanlzed using a Harvard Apparatus Anesthetizing box (Holliston, Massachusetts). 
About 5 pounds per square inch of C02 flowed Into the chamber for about 1 minute. Death was 
confirmed by testing reflex loss in the hind legs in adults or a physical secondary method for 
neonates. The mice were then placed in plastic bags and frozen until disposal. 
Mice were supplied with ample food and water and were kept on a 14 hour light and 10 
hour dark cycle each day. Cages were cleaned once a week. The mouse colony was kept In a 
temperature range of 18-26·c and a humidity range of 30.70%. At 10 days of age, ears of the 
mice were punched for identification and a 1-2mm tail biopsy was obtained after applying 
Gebauer's Ethyl Chloride• spray (Gebauer Company, Cleveland, OH) to the tail, which acts as a 
local anesthetic. The tail biopsy provided a DNA sample for genotyplng. After 3 weeks, the mice 
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were weaned from their mothers into cages containing no more than three males or three 
females. 
DNA Extraction. Each tall biopsy was submerged In 500 J.ll of Proteinase K buffer which 
contained 10 mM Trls pH 8, 190 mM NaCI, 100 mM EDTA pH 8, and 0.5% SDS, and Proteinase K 
to a final concentration of 0.25 mg/ml In order to digest all proteins In the tall. The biopsy In 
solution was then placed in a 55·c water bath overnight. To each ofthe samples, NaCI was 
added to a final concentration of 2M in order to separate proteins from the DNA. The tubes 
were then shaken and placed on Ice (o·c) for 10 minutes. The tubes were spun at 9500 rpm for 
10 minutes, further separating the proteins from the DNA. The supernatant was then poured 
into a new tube containing 1 ml of 95%-100% ethanol. After inverting, the samples were spun 
again at 14000 rpm for 10 minutes separating the DNA from other components due to its 
insolubility in ethanol. After removing the supernatant, 500 J.&L of 70% ethanol was used to 
wash the DNA pellet and then removed, which allowed the pellet to dry for 10-15 minutes. The 
pellet was resuspended in 100 IJL of TE buffer, which contained 10 mM Trls pH 8 and 1 mM 
EDTA pH 8. 
PCR. The DNA extracted from each of the tall biopsies was then used to genotype each 
of the offspring from the different matings by using polymerase chain reaction for DNA 
amplification. Each reaction tube contained 11JL of mouse tall DNA, 20 J,&L of sterile water, TAQ 
Master Mix (QIAGEN, Valencia, CA) to a final concentration that was SO% of its Initial 
concentration, and two primers (Integrated DNA Technologies, Coralville, lA) to a final 
concentration of 0.4 IJM for each, allowing for the detection and identification of the desired 
DNA segment. In order to detect if the DNA extraction was successful, a positive control using 
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primers CBR20R (5' CTCACGGTCATCTGGCTTCT 3') and CBR20F (5' CTGCTCCTTCTTCTGGGCTT 3') 
resulting in a 513 base pair product was used. For the detection of the PyVT oncogene, primers 
P003 (5' CAAATGTTGCTTGTCTGGTG 3') and P004 (5' GGAAAGTCACTAGGAGCAGGG 3') resulting 
in a 556 base pair product were used to ensure that the mice would develop mammary tumors. 
In order to detect if the mice were trisomic for the DSCR, two reactions were used to ensure 
that the actual gene of Interest was amplified and that the animal was definitively positive or 
negative for the trisomy. The primer sets for these two reactions were as follows: HYG19F (5' 
CCGTCAGGACATTGTIGGA 3')/HYG19R (5' CCGTAACCTCTGCCGTTCA 3') resulting in a 661 base 
pair product and CBRHF28 (5' CACCTTCTTCTCCAACCGTC 3')/MXPR2 (5' 
CCACCAAAGAACGGAGCC 3') resulting in a 392 base pair product. In order to detect if the mice 
were monosomic for the DSCR, the following primer set was used: MXPF2 (5' 
GGACGGTTGGAGAAGAAGGT 3')/CBRHR2 (5' CTCGTCCTGCAGTTCATTCA 3') resulting In a 349 
base pair product. To assess If the appropriate mice contained the null Cbrl allele, HYG19R (5' 
CCGTAACCTCTGCCGTTCA 3') and HYG19F (5' CCGTCAGGACATTGTTGGA 3') primers were used. 
Two reactions were used to ensure that the gene of Interest was amplified and that the animal 
was definitively positive or negative for the null Cbrl allele. The primers CBRHF2B (5' 
CACCTTCTTCTCCAACCGTC 3'} and CBRHR2 (5' CTCGTCCTGCAGTTCATTCA 3') were used for 
definitive confirmation. The reactions were run on the Bio-Rad DNAEngine Peltier Thermal 
Cycler. For the positive CBR20R/CBR20F control, and the HYG19F/HYG19R, CBRHF2B/MXPR2, 
MXPF2/ CBRHR2, and CBRHF2B/CBRHR2 primer sets, the CBR program was used. The CBR 
program began with 2 minutes at 94"C. Then 30 cycles at 94"C for 30 seconds, 55"C for 1 
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minute, and 1rc for 45 seconds followed. Each reaction ran for an additional 7 minutes at 1rc 
to allow the TAQ to finish, then was kept at 4"C until ready for gel electrophoresis visualization. 
The reactions using the P003/P004 primer set were amplified using the PYVTTDN, or 
PyVT touchdown, program. The PYVTTDN program began at 94"C for 2 minutes. Then 10 cycles 
were run, each consisting of 92"C for 30 seconds, 62"C for 30 seconds, and 72"C for 45 seconds. 
After each cycle, the temperature decreased In the second step 1"C from 62"C each cycle. Then 
25 cycles at 92"C for 30 seconds, 52"C for 30 seconds, and 72"C for 45 seconds were run. An 
addltlonal7 minutes at 72"C were run, and then reactions were stored at 4"C. 
Gel Electrophoresis. In order to visualize the PCR products, gel electrophoresis with a 
1% agarose gel was used. The 1% agarose gel was comprised of 100 ml of 1X TAE buffer, which 
contained 40 mM Trls acetate and 1 mM EDTA pH 8, and 1 g of analytical grade agarose. The 
buffer and agarose were combined in a 250 ml flask, weighed and zeroed, and then 
microwaved for two minutes until all the agarose was dissolved. The flask was then weighed 
and any water lost through evaporation was added until the flask reached its original weight. 
Ethldlum bromide was then added to the cool flask .to a final concentration of 5).lM. After the 
gel apparatus was in place, the gel was poured, combs inserted, and bubbles removed. After 
allowing the gel to solidify for 10 minutes, the apparatus was rotated and the gel was 
submerged in "'650 ml of 1X TAE buffer. Ethidium bromide was then added to the buffer to a 
final concentration of 5.8 IJM. To each ofthe PCR reactions, 5 JJL of loading dye was added to a 
final concentration of lX. Then, 5 J.ll of 2-log DNA ladder (New England Biolabs, Ipswich, MA) 
was added to the first lane, followed by 10 !JL of each reaction saniple to the subsequent lanes. 
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The gel was run at 150V for 45 minutes and then was visualized using a UVP (Upland, CA) Gel 
Doc-It Imaging System with Firstllght UV illuminator on Lab Works 4.6. 
Palpation. Mice containing the PyVT oncogene were palpated twice a week to detect 
any tumor formation or growth. Once a tumor was detected, measurements of the length and 
width of the tumor were taken using digital calipers and then recorded. Approximate volumes 
ofthe tumors were calculated using the equation: volume= (width2 x length)/2 due to the 
immeasurabillty of depth into the body cavity. The tumors were measured and mice were 
palpated for new tumors twice a week until a total tumor burden of "'1000 mm3 was reached, 
when the animal was sacrificed using the C02 chamber. 
Lung Inflation and Extraction. Once mice reached the total tumor burden of "'1000 
mm3, their lungs were obtained and analyzed for metastasis. Mice were sacrificed using a C02 
chamber and immediately dissected. The diaphragm was punctured and the sternum and rib 
cage were removed, deflating and allowing visual access to the lungs respectively. Each side of 
the mandible was cut through until the trachea was visible. Using an 18 gauge needle and 5 mL 
syringe, Fekete's solution (61% ethanol, 4.4% Glaciai·Acetic Acid, and 3.3% Formalin made just 
prior to injection) was Injected through the trachea Into the lungs, in order to Inflate and fix the 
lungs. The lungs were then dissected out, rinsed in water, separated (right lobes from left 
lobes) into their own so mL conical tubes, and submerged in Fekete's solution overnight. After 
24 hours, the lungs were then transferred into 70% ethanol for long term storage. 
Lung Metastasis Counts. Using a dissecting microscope, the metastases were counted. 
The lungs were placed in a clean petri dish. Using the dissecting microscope, the metastases on 
each lobe from each side of the lungs were counted and recorded. Large me~astases were 
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classified as being ~1 mm in diameter, while sman metastases were classified as being <1 mm In 
diameter. Data were recorded and input Into a Microsoft Excel (Albuquerque, NM) file. 
Data analysis. Data were double-keyed using Microsoft Excel and compared using SAS 
statistical analysis software (Cary, NC). Once matched, tumor latency, multiplicity, total tumor 
burden, and metastasis rate were computed using SAS. Box and whisker plots were created 
using TIBCO Spotfrre S+ software (Somervll.le, MA). The median (center), middle 50% of the data 
points (interquartlle range, IQR), and the lowest and highest values bounded by lower quartlle-
l.S(IQR) and upper quartile+l.S(IQR) were indicated. Any potential outliers were indicated by 
symbols plotted outside of the fences. Latency was assessed by measuring the period of time 
before onset of tumor formation for each mouse. Multiplicity and tumor burden were assessed 
by counting the number of tumors for each mouse and by calculating tumor burden by 
summing total tumor mass, respectively. Multiplicity and tumor burden data were similarly 
organized into box and whisker plots. Surface metastasis counts were conducted for each 
mouse sacrificed. Standard error within each genotype was considered when comparing data 
between groups. 
Results 
Matlnss 
Several types of matings were required for this study. Mice that were either monosomic 
(MslRhr) or trisomic (TslRhr) for the DSCR were bred to PyVT mice that contained the PyVT 
oncogene, In order to produce mice with alterations in mouse chromosome 16 that would 
theoretically develop tumors. In order to maintain the MslRhr and TslRhr lines, the mice were 
bred back to their respective backgrounds. Mice that were heterozygous knockout for the Cbr1 
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gene (+/-), bred on 86 or 129 backgrounds, were also bred to PyVT mice that would enable 
tumor development in progeny. The B6Cbr1+/- and 129Cbrl+/- lines were maintained as well. 
To genotype the mice that were bred throughout the study, gel electrophoresis was used to 
visualize the PCR products from each DNA tall biopsy. Figure lis a representative gel used to 
genotype the mice. 
Figure 1: Gel electrophoresis used to type for TslRhr. Lane 1 in each reaction contains a 
molecular weight marker. Lanes 2-7 for each reaction contain PCR products from different DNA 
samples. Lanes 2-7 from the positive control reaction are the results from the PCR reaction 
using primers CBR20R/CBR20F to ensure that DNA was successfully extracted from the tail 
sample and that the PCR protocol was functioning properly, as indicated by the bands In lanes 
2-7 at 513 base pairs (bp). Lanes 2-7 from the TslRhr #1 reaction contain the PCR products 
amplified using primers HYG19F/HVG19R, depicting two bands In lanes 4 and 7 at 661 bp. Lanes 
2-7 from the Ts1Rhr#2 reaction, a confirmatory reaction for the TslRhr genotype, contain the 
products of the PCR reaction using primers CBRHF2B/MXPR2. Two bands are depicted In lanes 4 
and 7 at 392 bp, Indicating that those samples, in both TslRhr reactions, contained amplified 
DNA specific to the primers used and that those mice are TslRhr positive. Lanes 2, 3, 5, and 6 
do not show bands; therefore, those samples are TslRhr negative, or wild type. In each 
reaction, lane 8 was used as a water control and lacked DNA sample to ensure that the reaction 
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mix used was not contaminated. Each water control did not produce a band; therefore, the 
reaction mix was uncontaminated. 
Once genotyped, the matlngs and resultant mice were analyzed using a chi-square test 
to assess Inheritance where p-values less than 0.05 were considered statistically significant. 
Such values would indicate that the observed genotypes are contrary to the null hypothesis and 
do not follow Mendelian dominant genetics. 
#of Mice I 
" I 
0.57297598 
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Table 1: Genotyping data. Each color represents a different mating conducted. Pale Purple 
Ts1Rhr; Pale Green Ms1Rhr; Pale Blue 129Cbrl+/-; Light Red B6Cbrl+/-; Pale Orange PyVI'; Dark 
Purple PyVI' x TslRhr; Green PyVI' x MslRhr; Blue PyVT x 129Cbrl+/-; Crimson PyVT x 
B6Cbr1+/-. Observed percentage was calculated by dividing the mice with each specific 
genotype by the total mice from that mating. Only male progeny from the PyVI' mating were 
genotyped as females do not transmit the oncogene to offspring. Matlngs to generate test mice 
(e.g. Ts1Rhr PyVT) were typed for PyVTfirst and those without the oncogene were not 
genotyped further, reflected by empty boxes. Each mating was expected to follow Mendelian 
genetics. Observed and expected values were compared using a chi-square test and p-values 
are indicated. Unknown genotypes were excluded from analysis. 
A total of 488 mice were typed, the majority from the matlngs that were conducted In 
order to maintain the lines. A total of 79 mice were produced through the Ts1Rhr mating to 
maintain the line and as indicated by the p-value of 0.57, the additional DSCR was inherited in a 
Mendelian fashion. The MslRhr matings to maintain the line produced a total of 77 mice; the 
genotypes were statistically compared and a p-value of 0.081 was calculated (Table 1), 
Indicating the wild type and Ms1Rhr progeny were statistically equivalent, as expected. The 
129Cbrl+/- and B6Cbrl+/- matlngs to maintain their lines required 49 and 62 mice to be typed 
for each group, similarly resulting In high p-values of 0.47 and 0.31, respectively (Table 1). The 
PyVT matlngs to maintain the PyVT line of rna les capable of transmitting the oncogene resulted 
In a total of 23 males typed with a p-value of 0.53 (Table 1). 
The PyVT x Ts1Rhr, PyVT x MslRhr, PyVT x 129Cbrl+/-, and PyVT x B6Cbrl+/- matings to 
produce mice that were studied for tumor growth and development produced 81, 42, 23, and 
49 mice, respectively. With high p-values of 0.59, 0.07, 0.11, and 0.10.(Table 1), the inheritance 
of both the PyVT oncogene and either alteration of mouse chromosome 16 followed Mendelian 
genetics. However, the percentage of mice with the MslRhr genotype and PyVT oncogene were 
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fairly low (14%) compared to the expected 25% percent, highlighting a trend of possible 
lethality associated with the monosomy (Table 1). 
Data Analysis 
Following collection of genotype and tumor data, preliminary data analysis was 
conducted. For 98 mice that generated tumors, identification Information and corresponding 
data were Input Into Microsoft Excel, generating files of 2298 (DSCR study) and 1519 (Cbr study) 
rows. To ensure the data was Input correctly, duplicate Hdouble-keY' flies were created. Data 
for the 98 test mice were Input again into new Excel flies. The design and use of different 
statistical analysis programs, SAS and Spotflre S+, were then learned. Using SAS statistical 
analysis software, the two duplicate flies were compared for input accuracy. Discrepancies 
were highlighted by the program output and resolved between the two flies. Once the data 
comparisons resurt:ed In 100% agreement, SAS programs designed to compare different 
variables between mouse identification information (e.g. genotype) and tumor Information 
(e.g. total tumor mass at death) were run. Data programs were then transferred to S+ In order 
to generate preliminary representations of the data. 
Due to the nature of the project utilizing an animal model, collection of data for each 
sex and genotype within each background for a representative sample size takes extended 
amounts of time. SAS and S+ analysis allowed for descriptive, visual tracking of the data 
throughout collection, but do not provide p-values. Because the project Is ongoing, qualitative 
analyses can suggest which comparisons look promising and may prove significant when future 
regression analyses can be conducted on a larger sample size to generate p-values. The results 
below are descriptive representations of the data collected over two years. 
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Tumor Latency 
Tumor latency analyses assessed the time before each mouse began developing tumors 
by determining the number of days between birth and first tumor formation. Figure 2 depicts 
the latency for TslRhr and MslRhr mice, separated by genetic background and sex. Figure 3 
depicts the latency for Cbr1+/~ similarly. The mice were divided to avoid false trends caused by 
variables that could possibly affect latency, such as sex and background. Different backgrounds 
consist of different alleles that are characteristic of that specific group and could also have an 
effect on latency. Data are represented in quartiles, representing the mean data points and 
detailed variation from that mean. 
300 
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n= 1 
_...._, 
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MslRhr 
Tumor Latency 
!iiltlmfWnet P'W.T81Rhr. T 
n=5 n= 1 n=4 
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- -
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Figure 2: Latency in days for MslRhr PyVT and TslRhr PyVT mice. Data are represented In box 
and whisker plots for MslRhr PyVT and WT PyVT llttermates and TslRhr PyVT and WT PyVT 
littermates, divided into males and females. The middle 5096 of data points within the blue box 
represent the interquartlle range {IQR), where the median is indicated by the red dot. The 
lower and upper quartlles (2596) are bound by ±1.5 x (IQR). Any outliers are indicated by a black 
circle. Genotype is indicated below each plot (WT=wlld type). 
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Male mice from both backgrounds tended to have a longer latency, or time until first 
tumor detection, than females from both backgrounds (Figure 2). However, there did not seem 
to be any promising differences between females within or between either background. 
Although males within the same background did not show differences In latency, males from 
the TslRhr background tended to develop tumors later than males from the MslRhr 
background (Figure 2). 
700 -
+I+ +J. +I+ +1-
Sr ~ 
::'\18 IJOCtn 
300 n=6 r =1 n=-8 li=S 
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• I+ .. ,. .,. +I-
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Figure 3: Latency in days. Data are represented In box and whisker ~lots for 129Cbrl+/- PyVT 
and wr (+/+) PyVT llttermates and B6Cbrl+/- PyVT and WT (+/+) PyVT littermates, divided Into 
males and females. Data is represented as detailed In Figure 2 legend. 
Similarly, female mice of both Cbr1 genotypes from both backgrounds tended to 
develop tumors earlier than males (Figure 3). Within the 129Cbrl+/- PyVT background, the 
males demonstrated that+/- mice tended to develop tumors slightly earlier than their wild type 
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littermates (Figure 3). However, few other comparisons between +/+and +/- groups warranted 
trends suggesting future promise. 
Tumor Multlplldty 
Tumor multiplicity, the number of tumors at death accumulated by each mouse, was 
Genotype 
Figure 4: Multiplicity oftumors at death for MslRhr and TslRhr PyVT background mice. Data 
presented as in Figures 2 & 3. 
Female mice of both genotypes within each background tended to have a higher tumor 
multiplicity at death when compared to male mice (Figure 4). Male mice from both the MslRhr 
PyVT and TslRhr PyVT backgrounds did not suggest any differences between tumor 
multiplicities. However, MslRhr females developed fewer tumors than their wild type 
littermates, whereas TslRhr females developed more tumors than their wild type littermates 
(Figure 4). 
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Figure 5: Multiplicity of tumors at death for 129Cbrl+/- and B6Cbrl+/- PyVT background mice. 
Data presented as In Figures 2-4. 
Similarly, female mice of both Cbrl genotypes within each background developed more 
tumors by death than male mice (Figure 5). However, no other comparisons between or within 
backgrounds suggested promising trends. 
Total Tumor Burden 
Total tumor burden was obtained by summing the total tumor volume for a given 
mouse on a given day throughout the study, the first volume indicating a particular mouse's 
first tumor detection. Males and females were divided again to negate latency differences 
between the sexes. 
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Total Tumor Burden: Ts1 Rhr & Ms 1 Rhr Males 
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Figure 6: Total tumor burden of males from MslRhr Pyvr and TslRhr PyVT backgrounds. Each 
mouse was designated a unique color and each circle of that color indicates total tumor volume 
for that mouse on the given day. Data qualitatively show the rate at which total tumor volume 
Increases. Early increases Indicate rapid tumor growth, whereas delayed Increases Indicate slow 
tumor growth. Trend lines should be Ignored as they quantitatively model regression of 
unequal data between mice. Empty boxes should be ignored. (Due to program constraints, S+ 
generated data boxes for MslRhr within the TslRhr background and for TslRhr within the 
MslRhr background for which no mice or data were possible.) 
Due to sample size constraints and variability in growth patterns within each group, no 
trends could be suggested from the qualitative representation of tumor burden progression in 
TslRhr and MslRhr males (Figure 6). 
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Figure 7: Total tumor burden of females from Ms1Rhr PyVT and Ts1Rhr PyVT backgrounds. Data 
presented as in Fisure 6. 
Similar to Figure 6, o"erlap of colored data dots within substantial samples for each 
group suggested that no promising trends existed between Ms1Rhr, TslRhr, and respective 
wild type females (Figure 7). 
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Figure 8: Total tumor burden of males from 129Cbrl+/- PyVT and B6129Cbrl+/- PyVT 
backgrounds. Data presented as In Figure 6. 
Within the 129Cbrl+/- PyVT background, the male +/+and +/-mice from comparable 
sample sizes tended to exhibit varied tumor growth, independent of genotype (Figure 8). No 
differences between the B6Cbrl+/+ and B6Cbrl+/- small samples was suggested, however 
(Figure 8). 
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Figure 9: Total tumor burden of females from 129Cbr1+/- PyVT and B6Cbr1+/- PyVT 
backgrounds. Data presented as in Figure 6. 
No comparisons between 129Cbrl+/- PyVT and B6Cbrl+/- PyVT or their respective+/+ 
littermates suggested promising differences or trends (Figure 9). 
Metastasis 
Following lung Inflation and extraction, lung metastasis surface counts were obtained by 
using a dissecting microscope. Average number of surface metastases for each of the subject 
groups, MslRhr PyVT and wild type littermates, TslRhr PyVT and wild type littermates, 
129Cbrl+/- PyVT and 129Cbr1+/+ wild type littermates, and B6Cbr1+/- PyVT and B6Cbr1+/+ 
wild type littermates were calculated as well as standard error. Counts were not separated 
based on sex due to the lack of statistical difference between males and females within the 
same group when compared using a Student's t-test as indicated by p-values greater than 0.05 
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(data not depleted). Metastases counts were divided into numbers of large and small 
metastases due to statistical differences (p<0.05) between large and small numbers of 
metastases within both WT groups of Ms1Rhr and Ts1Rhr matlngs (p= 0.0210 and p= 0.0130, 
respectively) and within both+/~ groups of 129Cbr1+/- and B6Cbr1+/- mice (p= 0.0500 and p= 
0.0497, respectively). 
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Figure 10: Average number of surface lung metastases for the four DSCR subject groups of both 
males and females combined. Variability of the mean value of metastases was assessed and 
Indicated by the standard error bars. Small and large metastases were compared to each group 
using a Student's t-test. Only p~values resulting from comparisons between aneuploid and 
euploid littermates are Indicated. All other p~values were Insignificant with p~values greater 
than 0.05. 
No significant trends seemed to be present within the surface metastasis count data. No 
significant differences in large or small metastasis development between aneuploid mice and 
their euploid littermates existed (Figure 10). 
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Figure 11: Average number of surface lung metastases for the four Cbr1+/- subject groups of 
both males and females combined. Variability of the mean value of metastases was assessed 
and Indicated by the standard error bars. Small and large metastases were compared to each 
group using a Student's t-test. Only p-values resulting from comparisons between aneuploid 
and euploid llttermates are indicated. All other p-values are below 0.05 and Indicate 
Insignificant differences between groups compared. 
Although no significant difference was detected in these surface metastasis count data, 
the 129Cbr1+/- did suggest a reduced number of small metastases when compared to 129 +/+ 
littermates (Figure 11). 
Discussion 
Population studies have been conducted and convincingly suggest that there Is a 
decreased Incidence of a variety of types of solid tumors in the Down syndrome popu latlon 
(Patja et at., 2006; Sullivan et al., 2007; Haste et at., 2000; Satge et al., 1998). This phenomenon 
that has been seen In populations throughout the world has led to the hypothesis that there Is 
a tumor suppressor gene within chromosome 21 and when increased in dosage, as seen in 
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Down syndrome, solid tumor suppression results. Our study Investigated both the effects of an 
altered dosage of the DSCR and of Cbr1, specifically on mammary tumor development and 
metastasis to the lungs in mice. 
Latency is a measure of tumor development and progression. "T:he DSCR and/or 
surrounding genes are theoretically harboring a tumor suppressor gene that could affect that 
progression; therefore, we would expect mice trisomic for the DSCR to exhibit a longer latency, 
developing cancer later In response to the supposed protective effects of the tumor suppressor 
gene. Those mice monosomic for that region would be expected to exhibit a shorter latency 
due to the Jack ofthose effects. Similarly, mice with both copies of Cbr1 (+/+)would be 
expected to benefit from the hypothesized prophylactic effects of CBR1, exhibiting a similar 
longer latency, whereas mice heterozygous for Cbr1 knockout(+/·) would be expected to show 
a shorter latency due to the missing tumor suppressor gene. Umemoto et al. (2001) used 
immunohistochemistry to determine that when CBR1 was reduced In ovarian cancer tissues, 
prognosis for patients was correlatively lower due to an increase in invasive progression 
through angiogenesis. lfthe trend suggested by Umemoto et al. (2001) and Takenaka et al. 
(2005) holds true, then the 129 and B6 mice with decreased Cbr1 expression (Cbrl+/-) will have 
a shorter latency due to an Increase ability to progress and invade tissues. Existing non-small-
cell lung cancer tissues were analyzed for the presence of CBR1 expression (Takenaka et al., 
2005). Quantified by real-time reverse transcription-PeR, a technique that reverse transcribes 
targeted RNA Into Its complementary DNA (eDNA) and then further amplifies and quantifies the 
eDNA, CBR1 mRNA was found to be reduced in invasive tumors and increased in tumors that 
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had not yet Invaded, In accordance with Umemoto et al.'s (2001) findings (Takenaka et al., 
2005). 
In our study, however, few trends suggest latency differences due to the alteration of 
gene dosage from chromosomal alterations. When comparing aneuploid mice to their 
respective euploid littermates of the same sex and background, few promising trends can be 
suggested from the descriptive data representations (Figures 2 & 3}. The exception includes 
129Cbrl+/- male mice who developed tumors earlier than their+/+ llttermates (Figure 3), 
supporting Cbrl's tumor suppressive capability claimed by Umemoto et al. (2001) and Taken aka 
et al. (2005). The 129Cbr1+/- male mice, however, seem to be the exception to the rule In the 
data in this study. This group Is the only model In this study supporting our hypothesis that a 
tumor suppressor is affecting tumor latency. 
The results do show that mice of different sexes exhibit different latencies; males began 
developing tumors much later than females (Figures 2 & 3). Other studies, such as those 
conducted by Lifsted et al. (1998) and Maglione et al. (2001) utilized only female mice. Possibly 
due to circulating estrogen that causes mammary tissue growth and subsequent effects on 
PyVT oncogenic tumor development, the latencies were possibly shortened due to hormonal 
differences alone (Lifsted et al., 1998; Maglione et al., 2001). However, our study includes both 
male and female mice to allow for comparisons of tumor and metastasis development In both 
sexes to be made. Sex has been shown to affect latency in previous studies involving the 
transgenic PyVT mouse model, with females developing tumors as early as 28 days following 
birth and males from the same line as early as 63 days (Guy et al., 1992). 
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The results of this study also suggest that different backgrounds affect the latency of 
tumor development; males bred on a 86 background (TslRhr and WT) exhibited a longer 
latency compared to male mice bred on a B6C3 background (MslRhr and WT) (Figure 2). In a 
study conducted by Lifsted and colleagues (1998), mice bred from different strains, with 
different genetic backgrounds, also varied in time of initial tumor development. Two strains 
developed tumors 20.6 and 17.8 days earlier, respectively, than the reference strain, while 
seven other strains experienced a delay of ~1 week In development of primary tumors (Lifsted 
et al., 1998). When comparing the129Cbrl+/- and B6Cbrl+/- males, their latencies differ 
between background as well; the B6Cbrl+/- and+/+ male mice are both developing tumors 
earlier than 129Cbr1+/- and+/+ matched groups (Figure 3). 
Tumor multiplicity was obtained by determining the number of tumors per mouse 
within each background and sex. A similar study was conducted that utilized the transgenic 
Ts65Dn model, which Is trisomic for a portion of mouse chromosome 16, as well as the Ts1Rhr 
model. An Intestinal ApcM1"-medlated tumor model was used to Induce tumors within the 
transgenic models to analyze multiplicity differences between the models. The Investigators 
found that both the Ts65Dn and TslRhr mice developed fewer tumors than their wild type 
littermates, for a total reduction In tumor development by 44% in mice with the trisomy 
(Sussan et al., 2008). Although our data reflect the effects of sex and subsequent differences In 
hormone~ on tumor development, no trends are lndlc.ative of a similar reduction In multiplicity 
due to mouse chromosome 16 alterations. In complete opposition to Sussan et al. (2008), the 
female mice In this study present an alternate trend as Ts1Rhr females developed more tumors 
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than wild type littermates (Figure 4). This trend, If It holds with an Increase In sample size, could 
lead to future Investigation of the effects of sex on this model. 
Tumor formation in the Ms1Rhr mice was also assessed by Sussan and colleagues 
(2008). Seeing a dramatic 101% Increase in Intestinal tumor development between Ms1Rhr 
mice and their wild type littermates, the researchers concluded that the deletion of the DSCR 
played a significant role In increased tumor multiplicity (Sussan et al., 2008). Conversely, the 
results of our study indicated that Ms1Rhr females (n=9) have a reduced tumor multiplicity 
when compared to their respective wild type llttermates (n=9) (Figure 4). These results suggest 
the DSCR may have a different effect in the two sexes. 
Due to the differences between male and female anatomy (considered in our study) and 
the differences between our breast cancer model and an Intestinal cancer model (Sussan et al., 
2008), another modifier could possibly be having an effect on tumor development in this study 
that was not a factor in Sussan and colleagues' intestinal tumor model. If this unexpected trend 
continues with more data collection, it can be concluded that sex clearly affects tumor 
development influenced by the DSCR. Nonethess, the implications of the striking differences 
between the results of Sussan and colleagues's Intestinal tumor model and the results of our 
study's mammary tumor model may beth~ result of a tissue-specific tumor suppressor. 
Although the presence of a tumor suppressor gene has been strongly suggested by a reduction 
in ApcMin trisomic mice (Sussan et al., 2008), perhaps the gene only suppresses intestinal 
tumors and Is Ineffective against cancerous mammary tissue. 
Total tumor burden was obtained by compiling total tumor volume for each mouse on a 
given day of measurement and mapping the progression In volume throughout the study. 
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Although results are descriptively represented at this point in the study, it can be grossly 
generalized that no promising trends are highlighted (Figures 6-9). However, other studies 
utilizing techniques different from the techniques employed in this study showed reductions in 
cell proliferation or suggested that the presence of a particular chromosome 21 tumor 
suppressor gene confers protective effects against ar.nasslng large tumors (Kwak et al., 2007; 
Laffin et al., 2008). In vitro, Kwak et al. (2007) re-established SIM2s In breast cancer cells that 
had lost SIM2s throughout cancer progression and observed a significant reduction in 
proliferation of the cells (Kwak et al., 2007). Similarly, Laffin et al. (2008) saw Increased 
tumorigenesis In MCF-7 breast cancer cells that had reduced SIM2s expression. In addition, 
mice that exhibited a reduced expression of the SIM2s gene in vivo were injected with SIM2i 
MCF-7 cancer cells (Laffin et al., 2008). When compared to control mice, the SIM2s deficient 
mice developed larger tumors, suggesting a protective effect of the SIM2s gene that is found 
within the DSCR (Laffin et al., 2008). Both studies utilized methods that could possibly show 
different results when observed In humans or naturally occurring cancer development. The 
injection of cancerous cells Into the SIM2s deficient mice provides a perspective on the effects 
of cancerous cells without SIM2s In vivo (Laffin et al., 2008); however, the development of 
cancer due to an Injection is not naturally occurring or mimicked In humans. Moreover, the 
manipulated breast cancer cells with reestablished SIM2s expression supported what was seen 
in Laffin and colleagues' study (Kwak et al., 2007), but were similarly not observed in a naturally 
occurring bodily environment. Although these results suggest SIM2s tumor suppressive 
capability in vitro, its effects In vivo are. not mimicked in our study's mouse model. Injected cells 
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may not mirror progression of cancer in biological systems as effectively as the PyVT model, 
artificially idealizing the function of proteins that naturally may be insignificant. 
Similarly, the In vitro histological techniques utilized to examine CBRllevels in various 
cancerous and non-cancerous tissues highlight the possible unreliability ofthese types of In 
vitro conclusions. Umemoto et al. (2001) and Takenaka et al. (2005) suggest that the Inverse 
correlation between CBR1 and prognosis is due to CBRl's effect on cancer, but do not 
necessarily consider cancer's effect on CBRl. If CBR1ls lost during cancer progression, the 
probability of It taking effective action against cancerous proliferation may not be likely. The 
use of this 'Cbr1+/- animal model could elucidate the unknown cause of the ·correlation, but still 
has its limitations as the knockout of just one of the Cbrl+/- alleles may not be sufficient to 
detect significant deviation from the wild ·type. However, since Cbr1-/- mice are not viable, 
further reduction of Cbr1 is difficult (Olson et al., 2003). Overexpressing Cbr1 may be a route to 
assess the effects of altered Cbr1 dosage. 
Surface metastasis counts were obtained following lung inflation and extraction. 
Although previous studies have histologically analyzed tissues to obtain metastasis counts, 
using hematoxylin and eosin staining (Aimholt et at., 2003 & Martinet al., 2008), surface 
metastasis counts were pursued due to having been proven more cost and tlme.-efflclent for 
the researchers. However, both methods have suggested metastasis development is affected 
by genetic background (Martin et al., 2008). When assessing different matrix 
metalloprotelnases, enzymes Involved in the breakdown of the extracellular matrix, activities 
within the met~static process, researchers determined that metastatic outcome seemed 
dependent on genetic background (Martin et al., 2008), similar to tumor development and 
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latency. However, in our study, large standard error and p-values resulting from Student's t-
tests suggest that there is no statistical difference in large or small metastasis development 
between backgrounds {Figures 10 & 11). A study conducted by Lifsted et al. {1998) sussested, 
however, that transgene expression of PyVT is not solely sufficient to cause metastasis (Lifsted 
et al., 1998). Other factors must be Involved, and the alteration of gene dosage could possibly 
be one such factor causing secondary events that lead to variability in metastatic ability. 
Studies conducted to determine how genetic changes, specifically In expression, can 
modify metastatic progression suggested carbonyl reductase to be a new Intercessor in the 
malignant development of metastasis by reducing metastatic proliferation (Ismail et al., 2000). 
Following in vitro preparation, adenocarcinoma cells were injected Into mice in addition to an 
expression vector containing Cbrl eDNA (Ismail et al., 2000). The normally highly invasive 
cancer cells with a penchant for metastasis were halted and progression of the metastatic 
process was slowed (Ismail et al. 2000). Although no statistically promising trends were 
determined here, 129Cbrl+/- mice unexpectedly developed fewer small metastases than their 
+/+ littermates (Figure 11). If this trend c;ontinues and proves significant, the results promoting 
Cbrl-induced metastasis suppression following cancer Injection may be challenged. 
Many of the results obtained from this study stray from suggested trends concluded In 
other literature. Not only could differences be a result of methodological differences between 
studies, but variation within the data collected in this study. Within the same sex and 
background, mice developed tumors over a range of two years (Figure 3) or anywhere from 1 to 
10 tumors (Figure 5). This breast cancer model was chosen due to the accessibility of the 
tumors to new and rotating researchers. The mammary tumors grew outside of the body cavity 
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and allowed for relatively little training In order to detect and to measure tumors. However, 
several researchers with different palpating and measuring techniques participated In data 
collection. Although great efforts were made to ensure uniformity in measurement, variation is 
Inevitable. 
Due to Inherent biological variation between test animals, even within the same group, 
development of cancer can vary unpredictably. Because cancer initiation and development Is 
thought to require Knudson's illtwo-hitsR In ordet for cancer to result, these models expressing 
the PyVT oncogene are still biologically different from one another (Hino, 1997). Some animals, 
despite similar genetics and physiology, are still biologically variable and will receive their 
"second-hitu earlier than others, resulting In earlier cancer development. 
Despite this study's unexpected results that refute the candld~cy of Cbrl as a possible 
tumor suppressor gene or other genes within the DSCR, finding a tumor suppressor gene In any 
model could have positive implications and Is a YfOrthy pursuit. By eliminating Cbrl and the 
genes within the DSCR from the list of potential tumor suppressor genes, other models with 
genes conserved In human chromosome 21 could be tested. Identifying such a gene and its 
protein product, or narrowing down the possible candidates by processes of elimination, could 
possibly lead to the development of anti-cancer or cancer-reducing agents. Not only Individuals 
with Down syndrome, but all Individuals could benefit from the protectiv~ effects oftumor 
suppressor genes against the development and progression of cancer through the upregulation 
of that specific gene. ldentifying·a successful therapy, such as gene therapy, that mimics the in 
vivo environment that causes an Increase in transcription ofthe gene, could be used to increase 
the abundance of such a tumor or metastasis suppressor. 
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